Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (April 2025)
14 slides from Qiagen's investor day presentation, Apr 23, 2025
Slide 1: Deep Dive – QuantiFERON
Deep Dive QuantiFERON CLINICALLY PROVEN, GLOBALLY TRUSTED Deep Dive – QuantiFERON April 23, 2025
Slide 2: Tuberculosis is the world's deadliest infectious disease
TUBERCULOSIS IS THE WORLD'S DEADLIEST INFECTIOUS DISEASE Active TB Characteristics >10 million active cases globally(1) TB is actively spreading Symptomatic and contagious Testing through NAAT, Often deadly if not treated chest X-Ray, sputum culture TB disease Latent TB Characteristics TB infection
Slide 3: TB can only be overcome through latent TB testing
TB CAN ONLY BE OVERCOME THROUGH LATENT TB TESTING ~2 bn Treating only active cases … putting people across many people infected will not stop TB… groups at great risk with latent TB Deaths (per mn per year)(2) >75 mn Baseline Immunocompromised latent TB tests patients annually 100 >45 mn Nursing Dru
Slide 4: QuantiFERON is committed to the fight against TB
QUANTIFERON IS COMMITTED TO THE FIGHT AGAINST TB #1 IGRA globally >75 mn latent TB tests with >70% market share $454 mn 2024 net sales >130 countries North with QuantiFERON customers America across 3,100 labs ~35 mn EMEA Japan ~10 mn ~7 mn Highest endorsements Asia- Pacific ~$500 mn including WHO, C
Slide 5: Driving conversion with unrivaled automation
DRIVING CONVERSION WITH UNRIVALED AUTOMATION Significant skin test conversion opportunity Looking ahead Others ~40% Drive TB market Blood-based New decentralized conversion tests TB test for emerging Skin tests markets in 2027 ~60% ~70–80% ~$1.6 bn market size(1) QuantiFERON Leading universal automa
Slide 6: Constantly raising barriers to entry
CONSTANTLY RAISING BARRIERS TO ENTRY 1st generation QuantiFERON-TB 3rd generation QuantiFERON-TB Key achievements Breakthrough: Blood test to replace New benchmark: Scalable with 20+ years skin test remote incubation of experience and expertise 2004 2017 2001 2007 2nd generation 4th generation Quant
Slide 7: Bringing together industry leaders in technology and automation
BRINGING TOGETHER INDUSTRY LEADERS IN TECHNOLOGY AND AUTOMATION Serving customers with best-in-class technology Enabling scalable tests with superior automation QuantiFERON-TB Gold Plus Global universal automation workflow Proprietary technology (CD4 / CD8) Fully automated No cross-reaction with Ren
Slide 8: Dr. Chen Even Testimonial
Dr. Chen Even Testimonial Chief Commercial Officer Diasorin and QIAGEN partnership 8
Slide 9: QuantiFERON trusted by customers
QUANTIFERON TRUSTED BY CUSTOMERS Superior workflow Superior automation The standardization of an accurate test for TB Prior to running automated QuantiFERON TB screening removes the variability of performing testing, our lab was utilizing the T-spot method. a skin test read, which improved patient/e
Slide 10: Expanding with QIAreach to high disease burden and low-resource areas
EXPANDING WITH QIAREACH TO HIGH DISEASE BURDEN AND LOW-RESOURCE AREAS Increase access to best-in class QuantiFERON technology Global health commitments WHO 1 mL blood 16-24 hour Add test sample Readout on QIAreach strategy to eradicate collection incubation to cassette QIAreach Reader test result TB
Slide 11: Developing Lyme disease test addressing unmet needs
DEVELOPING LYME DISEASE TEST ADRESSING UNMET NEEDS Expanding into Lyme disease with Diasorin Rising U.S. occurrence of Lyme disease Number of cases(2) Improved early detection capabilities 90,000 Only test for acute-phase of Lyme disease 80,000 EU: Approved / U.S.: Submitted to the FDA 70,000 60,000
Slide 12: Why does QuantiFERON win?
WHY DOES QUANTIFERON WIN? Against skin tests (TST) Against other IGRAs QuantiFERON does NOT cross react with the BCG UNIVERSAL AUTOMATION WORKFLOW customizable vaccine while the TST leads to FALSE POSITIVES to labs of all sizes with fast time to result QuantiFERON only requires a SINGLE VISIT wherea
Slide 13: Established, Endorsed, Experienced
QuantiFERON – CLINICALLY PROVEN, GLOBALLY TRUSTED Global reach Established Used in 130+ countries with regulatory approval on 6 continents in labs and clinical workflows worldwide Relentless innovation Endorsed 20+ years of expertise and continuous development by global guidelines and expert bodies
Slide 14: QuantiFERON
QuantiFERON CLINCICALLY PROVEN, GLOBALLY TRUSTED ADVANCING MODERN LATENT TB TESTING WITH ACCURACY AND CONFIDENCE